Personalized (N-of-1) Trials for Depression: A Systematic Review

Overview

Journal J Clin Psychopharmacol

Specialty Pharmacology

Date 2018 Mar 30

PMID 29596148

Citations 14

Authors

Ian M Kronish

Meghan Hampsey

Louise Falzon

Beatrice Konrad

Karina W Davidson

Affiliations

Soon will be listed here.

Abstract

Purpose/background: Personalized (N-of-1) trials are single-patient, crossover-design trials that may be useful for personalizing the selection of depression treatments. We conducted a systematic review of published N-of-1 trials for depression to determine the feasibility and suitability of this methodology for personalizing depression care.

Methods/procedures: Electronic databases were searched from database inception through October 2016. Studies were selected if they enrolled depressed patients, included a within-subject crossover design, and systematically assessed depressive symptoms during the N-of-1 trial.

Findings/results: Five eligible studies reporting on 47 depressed patients (range, 1-18 patients) were identified. Two studies were conducted among adults with treatment-resistant depression, 1 study among depressed inpatients, and 2 studies among patients from special populations (geriatric nursing home, human immunodeficiency virus-associated encephalopathy). All studies evaluated the effects of pharmacologic treatments (methylphenidate, D-amphetamine, ketamine, and sulpiride). Three studies compared an off-label treatment with placebo, 1 study compared 2 off-label treatments, and 1 study compared escalating doses of an off-label treatment with placebo. All 4 studies with more than 1 participant demonstrated heterogeneous treatment effects. All studies produced data that could personalize treatment selection for individual patients. No studies reported on recruitment challenges, compliance with self-tracking, or satisfaction with participation.

Implications/conclusions: The feasibility of N-of-1 trials for depression was demonstrated for a limited number of second-line pharmacologic treatments in treatment-resistant patients or in patients with comorbidities that would have excluded them from conventional randomized controlled trials. Additional research is needed to determine whether N-of-1 trials are suitable for improving the selection of depression treatments in clinical practice.

Citing Articles

N-of-1 tests in general practice: pharmacological considerations.

Diezi L, Anastasi M, Brutus L, Buclin T Br J Gen Pract. 2025; 75(752):132-135.

PMID: 40016097 PMC: 11892778. DOI: 10.3399/bjgp25X740985.

Preclinical Development of Antisense Oligonucleotides to Rescue Aberrant Splicing Caused by an Ultrarare Variant in a Child with Early-Onset Stargardt Disease.

Suarez-Herrera N, Li C, Leijsten N, Karjosukarso D, Corradi Z, Bukkems F Cells. 2024; 13(7.

PMID: 38607040 PMC: 11011354. DOI: 10.3390/cells13070601.

Exploring human biology with N-of-1 clinical trials.

Schork N, Beaulieu-Jones B, Liang W, Smalley S, Goetz L Camb Prism Precis Med. 2023; 1.

PMID: 37255593 PMC: 10228692. DOI: 10.1017/pcm.2022.15.

N-of-1 Trials in Cancer Drug Development.

Gouda M, Buschhorn L, Schneeweiss A, Wahida A, Subbiah V Cancer Discov. 2023; 13(6):1301-1309.

PMID: 37070849 PMC: 10236153. DOI: 10.1158/2159-8290.CD-22-1377.

Correlation of damage score in PTOA with changes in stress on cartilage in an ovine model.

Vakiel P, Shekarforoush M, Dennison C, Achari Y, Muench G, Scott M Osteoarthr Cartil Open. 2022; 2(4):100109.

PMID: 36474890 PMC: 9718328. DOI: 10.1016/j.ocarto.2020.100109.

References

McGrath C, Kelley M, Holtzheimer P, Dunlop B, Craighead W, Franco A . Toward a neuroimaging treatment selection biomarker for major depressive disorder. JAMA Psychiatry. 2013; 70(8):821-9. PMC: 4413467. DOI: 10.1001/jamapsychiatry.2013.143. View

Cuijpers P, Reynolds 3rd C, Donker T, Li J, Andersson G, Beekman A . Personalized treatment of adult depression: medication, psychotherapy, or both? A systematic review. Depress Anxiety. 2012; 29(10):855-64. DOI: 10.1002/da.21985. View

Tate R, Perdices M, Rosenkoetter U, Shadish W, Vohra S, Barlow D . The Single-Case Reporting Guideline In BEhavioural Interventions (SCRIBE) 2016 Statement. J Clin Epidemiol. 2016; 73:142-52. DOI: 10.1016/j.jclinepi.2016.04.006. View

Hawton K, van Heeringen K . Suicide. Lancet. 2009; 373(9672):1372-81. DOI: 10.1016/S0140-6736(09)60372-X. View

Shamseer L, Sampson M, Bukutu C, Schmid C, Nikles J, Tate R . CONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration. J Clin Epidemiol. 2015; 76:18-46. DOI: 10.1016/j.jclinepi.2015.05.018. View

Rochon J . A statistical model for the "N-of-1" study. J Clin Epidemiol. 1990; 43(5):499-508. DOI: 10.1016/0895-4356(90)90139-g. View

Sniehotta F, Presseau J, Hobbs N, Araujo-Soares V . Testing self-regulation interventions to increase walking using factorial randomized N-of-1 trials. Health Psychol. 2012; 31(6):733-7. DOI: 10.1037/a0027337. View

Kronish I, Alcantara C, Duer-Hefele J, St Onge T, Davidson K, Carter E . Patients and primary care providers identify opportunities for personalized (N-of-1) trials in the mobile health era. J Clin Epidemiol. 2017; 89:236-237. PMC: 5774675. DOI: 10.1016/j.jclinepi.2017.06.008. View

Thakur M, Grossman I, McCrory D, Orlando L, Steffens D, Cline K . Review of evidence for genetic testing for CYP450 polymorphisms in management of patients with nonpsychotic depression with selective serotonin reuptake inhibitors. Genet Med. 2007; 9(12):826-35. DOI: 10.1097/gim.0b013e31815bf98f. View

10.

Little K . d-Amphetamine versus methylphenidate effects in depressed inpatients. J Clin Psychiatry. 1993; 54(9):349-55. View

11.

Gabler N, Duan N, Vohra S, Kravitz R . N-of-1 trials in the medical literature: a systematic review. Med Care. 2011; 49(8):761-8. DOI: 10.1097/MLR.0b013e318215d90d. View

12.

Kronish I, Hampsey M, Falzon L, Konrad B, Davidson K . Personalized (N-of-1) Trials for Depression: A Systematic Review. J Clin Psychopharmacol. 2018; 38(3):218-225. PMC: 5904006. DOI: 10.1097/JCP.0000000000000864. View

13.

Kessler R, Berglund P, Demler O, Jin R, Koretz D, Merikangas K . The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 2003; 289(23):3095-105. DOI: 10.1001/jama.289.23.3095. View

14.

Simon G . Choosing a first-line antidepressant: equal on average does not mean equal for everyone. JAMA. 2001; 286(23):3003-4. DOI: 10.1001/jama.286.23.3003. View

15.

Schmid C, Trikalinos T, Olkin I . Bayesian network meta-analysis for unordered categorical outcomes with incomplete data. Res Synth Methods. 2015; 5(2):162-85. DOI: 10.1002/jrsm.1103. View

16.

Loo C, Galvez V, OKeefe E, Mitchell P, Hadzi-Pavlovic D, Leyden J . Placebo-controlled pilot trial testing dose titration and intravenous, intramuscular and subcutaneous routes for ketamine in depression. Acta Psychiatr Scand. 2016; 134(1):48-56. DOI: 10.1111/acps.12572. View

17.

Ball T, Stein M, Paulus M . Toward the application of functional neuroimaging to individualized treatment for anxiety and depression. Depress Anxiety. 2014; 31(11):920-33. DOI: 10.1002/da.22299. View

18.

Donohue J, Pincus H . Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment. Pharmacoeconomics. 2006; 25(1):7-24. DOI: 10.2165/00019053-200725010-00003. View

19.

Rush A, Trivedi M, Wisniewski S, Stewart J, Nierenberg A, Thase M . Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med. 2006; 354(12):1231-42. DOI: 10.1056/NEJMoa052963. View

20.

Jansen I, Olde Rikkert M, Hulsbos H, Hoefnagels W . Toward individualized evidence-based medicine: five "N of 1" trials of methylphenidate in geriatric patients. J Am Geriatr Soc. 2001; 49(4):474-6. DOI: 10.1046/j.1532-5415.2001.49092.x. View